STACK Infrastructure’s Brian Cox Recognized Among National Safety Council’s CEOs Who “Get It”
Award further establishes STACK as prominent safety innovator in the digital infrastructure industry Denver, COLORADO…
News
Qualigen Therapeutics Chief Executive Officer Michael Poirier Provides Letter to Stockholders
CARLSBAD, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,”…
Qualigen Therapeutics Chief Executive Officer Michael Poirier Provides Letter to Stockholders
CARLSBAD, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,”…
Lisata Therapeutics Announces Participation in Upcoming Conferences in February
BASKING RIDGE, N.J., Feb. 01, 2023 (GLOBE NEWSWIRE) — Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”…
Lisata Therapeutics Announces Participation in Upcoming Conferences in February
BASKING RIDGE, N.J., Feb. 01, 2023 (GLOBE NEWSWIRE) — Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”…
Pardes Biosciences to Present at SVB Securities Global Biopharma Conference
CARLSBAD, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) — Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage…
Pardes Biosciences to Present at SVB Securities Global Biopharma Conference
CARLSBAD, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) — Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage…
ResolutionRx Ltd, a wholly owned subsidiary of RespireRx Pharmaceuticals Inc. Enters into LOI and Term Sheet with Radium Capital for the financing of anticipated Research and Development Credits
Glen Rock, N.J., Feb. 01, 2023 (GLOBE NEWSWIRE) — RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI)…
ResolutionRx Ltd, a wholly owned subsidiary of RespireRx Pharmaceuticals Inc. Enters into LOI and Term Sheet with Radium Capital for the financing of anticipated Research and Development Credits
Glen Rock, N.J., Feb. 01, 2023 (GLOBE NEWSWIRE) — RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI)…
Novo Nordisk files annual report with the SEC
Bagsværd, Denmark, 1 February 2023 – Novo Nordisk A/S has filed its Annual Report 2022…
Novo Nordisk files annual report with the SEC
Bagsværd, Denmark, 1 February 2023 – Novo Nordisk A/S has filed its Annual Report 2022…
Agile Therapeutics Provides Clinical Update on Twirla and Status of Pipeline Evaluation
FDA Agrees to Extended Milestones for Long-Term Twirla® Safety Study New Publication Supports Eventual Pursuit…
Agile Therapeutics Provides Clinical Update on Twirla and Status of Pipeline Evaluation
FDA Agrees to Extended Milestones for Long-Term Twirla® Safety Study New Publication Supports Eventual Pursuit…
Cue Biopharma to Present at Two February 2023 Scientific Conferences
BOSTON, Feb. 01, 2023 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company…
Cue Biopharma to Present at Two February 2023 Scientific Conferences
BOSTON, Feb. 01, 2023 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company…
Recludix Pharma to Present at the Guggenheim Healthcare Talks Oncology Conference
SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) — Recludix Pharma, a leader in platform approaches…
Recludix Pharma to Present at the Guggenheim Healthcare Talks Oncology Conference
SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) — Recludix Pharma, a leader in platform approaches…
Bolt Biotherapeutics to Present at February Investor Conferences
REDWOOD CITY, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) — Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage…
Bolt Biotherapeutics to Present at February Investor Conferences
REDWOOD CITY, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) — Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage…
Cidara Therapeutics and WuXi XDC Expand Collaboration for IND-enabling CMC Development to Advance Cidara’s CD73 Oncology DFC Program
Agreement builds upon the existing relationship with WuXi XDC for CMC development and GMP manufacturing…